High serum IL-21 levels after 12 weeks of antiviral therapy predict HBeAg seroconversion in chronic hepatitis B

Background & Aims Interleukin-21 (IL-21) stimulates T cell and B cell responses and plays a role in control of chronic viral infections. The role of IL-21 in chronic hepatitis B virus (HBV) infection is not understood. Methods Serum IL-21 levels were measured by enzyme immunoassay in 75 HBeAg-po...

Full description

Saved in:
Bibliographic Details
Published in:Journal of hepatology 2012-04, Vol.56 (4), p.775-781
Main Authors: Ma, Shi-Wu, Huang, Xuan, Li, Yong-Yin, Tang, Li-Bo, Sun, Xiao-Feng, Jiang, Xiao-Tao, Zhang, Yue-Xin, Sun, Jian, Liu, Zhi-Hua, Abbott, William G.H, Dong, Yu-Hong, Naoumov, Nikolai V, Hou, Jin-Lin
Format: Article
Language:English
Subjects:
Adult
Alanine Transaminase - blood
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiviral agents
Antiviral Agents - therapeutic use
Biological and medical sciences
Biomarkers - blood
Disease Progression
DNA, Viral - blood
Female
Gastroenterology and Hepatology
Gastroenterology. Liver. Pancreas. Abdomen
Hepatitis B e Antigens - blood
Hepatitis B virus - genetics
Hepatitis B, Chronic - diagnosis
Hepatitis B, Chronic - drug therapy
Hepatitis B, Chronic - immunology
Human viral diseases
Humans
Infectious diseases
Interleukins - blood
Male
Medical sciences
Nucleosides - therapeutic use
Pharmacology. Drug treatments
Pyrimidinones - therapeutic use
Reproducibility of Results
Sensitivity and Specificity
Severity of Illness Index
Thymidine - analogs & derivatives
Treatment Outcome
Viral diseases
Viral hepatitis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background & Aims Interleukin-21 (IL-21) stimulates T cell and B cell responses and plays a role in control of chronic viral infections. The role of IL-21 in chronic hepatitis B virus (HBV) infection is not understood. Methods Serum IL-21 levels were measured by enzyme immunoassay in 75 HBeAg-positive chronic hepatitis B (CHB) patients undergoing telbivudine treatment. The findings were validated in 103 patients from a separate clinical trial of telbivudine. A complete response to telbivudine was defined as having both HBeAg seroconversion and serum HBV-DNA level
ISSN:0168-8278
1600-0641
DOI:10.1016/j.jhep.2011.10.020